Recent Updates
Recently added Catalysts
SVRA Positive Sentiment

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Monday, October 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Savara Inc. announced that it will present new analyses from the Phase 3 IMPALA-2 clinical trial and deliver an encore presentation of long-term data on Molgramostim at CHEST 2026. The event will take place in Phoenix, Arizona, from October 18 to 21. This highlights the company's ongoing commitment to addressing autoimmune pulmonary alveolar proteinosis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Savara's data presentation highlights significant findings.
  • The company focuses on rare respiratory diseases, indicating a niche market.
  • The acceptance of presentations at a major conference underscores the relevance of their research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
7.6%
average across 6 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
Molgramostim
NDA/BLA · Autoimmune Pulmonary Alveolar Proteinosis

Full Press Release Details

YARDLEY, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an encore oral presentation on data from the Phase 3 IMPALA-2 clinical trial and a poster presentation on data from the Phase 2/3 IMPALA clinical trial at CHEST 2026 in Phoenix, Arizona, October 18–21. Oral Presentation Title: Long-Term Efficacy and Safety of Molgramostim in Patients with Autoimmune Pulmonary Alveolar Prote

Frequently Asked Questions

What is the focus of Savara Inc.?

Savara Inc. focuses on developing treatments for rare respiratory diseases.

When will CHEST 2026 take place?

CHEST 2026 will occur from October 18 to 21 in Phoenix, Arizona.

What data will Savara present at CHEST 2026?

Savara will present data from the Phase 3 IMPALA-2 trial and long-term data on Molgramostim.

What is Molgramostim used for?

Molgramostim is being investigated for its efficacy in treating autoimmune pulmonary alveolar proteinosis.

ShareAdd on Google
Tags: SVRA Savara Molgramostim aPAP CHEST 2026 clinical trial
Last updated: Oct 12, 2026

Biotech snapshot

Cash runway
$173M liquidity · $10M/mo burn
~15 mo
Low dilution risk
Lead asset
MolgramostimNDA/BLA
Autoimmune Pulmonary Alveolar Proteinosis →

Catalyst track record

+9%
best trade around SVRA's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for SVRA.

See every catalyst's timing & PoA →